A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

mAbs

Volumn 5, Issue 6, 2013, Pages 946-955

  Tan, Wenlong ^a   Meng, Yanchun ^b   Li, Hui ^c   Chen, Yang ^c   Han, Siqi ^c   Zeng, Jing ^c   Huang, Ang ^c   Li, Bohua ^b   Zhang, Yanyun ^a   Guo, Yajun ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bispecific antibody; Conformational change; Endocytosis; Hepatitis B virus; Neutralizing activity; Steric hindrance

Indexed keywords

C4D2 BS ANTIBODY; C4D2 MONOCLONAL ANTIBODY; C4G4 MONOCLONAL ANTIBODY; D2C4 BS ANTIBODY; D2H2 MONOCLONAL ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; EPITOPE; PEPTIDE;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG POTENTIATION; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LIVER CELL; MEMORY CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; VIRION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; BLOTTING, WESTERN; CELL LINE, TUMOR; EPITOPES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; PEPTIDES;

EID: 84889803644     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26390     Document Type: Article

References (36)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-29; PMID:15014185; http://dx.doi.org/10.1056/NEJMra031087
2. Wands Jr. Prevention of hepatocellular carcinoma. N Engl J Med 2004; 351:1567-70; PMID:15470221; http://dx.doi.org/10.1056/NEJMe048237
3. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38:533-40; PMID:12663250
4. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23:39-46; PMID:12616449; http://dx.doi.org/10.1055/s-2003-37583
5. Luk JM, Wong KF. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. Clin Exp Pharmacol Physiol 2006; 33:482-8; PMID:16700883; http://dx.doi.org/10.1111/j.1440-1681.2006.04396.x
6. Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009; 48:203-8; PMID:19179883; http://dx.doi.org/10.1097/MPG.0b013e3181819ad4
7. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991; 254:856-60; PMID:1658936; http://dx.doi.org/10.1126/science.1658936
8. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71; PMID:18449194; http://dx.doi.org/10.1038/nature06890
9. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009; 343:65-7; PMID:19100741; http://dx.doi.org/10.1016/j.jim.2008.11.012
10. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-40; PMID:19287373; http://dx.doi.org/10.1038/nature07930
11. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-61; PMID:20616233; http://dx.doi.org/10.1126/science.1187659
12. Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, Kadowaki S, Takahashi K, Sugiyama T, Kishi H, et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 2009; 15:1088-92; PMID:19684583; http://dx.doi.org/10.1038/nm.1966
13. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99:15655-60; PMID:12432097; http://dx.doi.org/10.1073/pnas.232137699
14. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010; 51:63-72; PMID:19877170; http://dx.doi.org/10.1002/hep.23230
15. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M, et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 2002; 35:673-9; PMID:11870383; http://dx.doi.org/10.1053/ jhep.2002.31867
16. Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, Dagan S, Naoumov NV. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 2010; 52:875-85; PMID:20593455; http://dx.doi.org/10.1002/hep.23778
17. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77:8882-92; PMID:12885906; http://dx.doi.org/10.1128/JVI.77.16.8882-8892.2003
18. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216
19. Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010; 18:630-40; PMID:21130043; http://dx.doi.org/10.1016/j.ccr.2010.11.001
20. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-70; PMID:18656541; http://dx.doi.org/10.1016/j. coi.2008.06.012
21. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
22. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, Ben-Moshe O, Kitchinzky A, Berr S, Gopher J, et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000; 32:588-96; PMID:10960454; http://dx.doi.org/10.1053/jhep.2000.9632
23. Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, Osterhaus A. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol 1999; 80:1529-35; PMID:10374972
24. Cheong HS, Chang JS, Park JM, Byun SM. Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem Biophys Res Commun 1990; 173:795-800; PMID:1702631; http://dx.doi.org/10.1016/S0006- 291X(05)80857-5
25. Madrenas J, Chau LA, Teft WA, Wu PW, Jussif J, Kasaian M, Carreno BM, Ling V. Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J Immunol 2004; 172:5948-56; PMID:15128776
26. Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res 1993; 53:3015-21; PMID:7686448
27. Vasu C, Gorla SR, Prabhakar BS, Holterman MJ. Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int Immunol 2003; 15:641-54; PMID:12697664; http://dx.doi.org/10.1093/intimm/dxg061
28. Khaw BA, Rammohan R, Abu-Taha A. Bispecific enzyme-linked signal-enhanced immunoassay with subattomole sensitivity. Assay Drug Dev Technol 2005; 3:319-27; PMID:15971993; http://dx.doi.org/10.1089/adt.2005.3.319
29. Roguin LP, Retegui LA. Monoclonal antibodies inducing conformational changes on the antigen molecule. Scand J Immunol 2003; 58:387-94; PMID:14507303; http://dx.doi.org/10.1046/j.1365-3083.2003.01320.x
30. Davies DR, Sheriff S, Padlan EA. Antibody-antigen complexes. J Biol Chem 1988; 263:10541-4; PMID:2455717
31. Lazear E, Whitbeck JC, Ponce-de-Leon M, Cairns TM, Willis SH, Zuo Y, Krummenacher C, Cohen GH, Eisenberg RJ. Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. J Virol 2012; 86:1563-76; PMID:22130533; http://dx.doi.org/10. 1128/JVI.06480-11
32. Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230:159-71; PMID:10594363; http://dx.doi.org/10.1016/S0022- 1759(99)00135-0
33. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-7; PMID:12920303; http://dx.doi.org/10.1126/science.1086907
34. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-24; PMID:17996249; http://dx.doi.org/10.1016/j.jim.2007.09.017
35. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402; http://dx.doi.org/10.4161/mabs.1.4.8755
36. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285